Tag: AstraZeneca

Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer

AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients

AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19

AstraZeneca-Merck genetic disorder treatment wins FDA nod

FDA Approves AstraZeneca’s First Therapy for Children with Debilitating and Disfiguring Rare Disease

Imfinzi approved in the US for extensive-stage small cell lung cancer

Farxiga reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

AstraZeneca divests global rights to Movantik (naloxegol)

Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer, not Progressed on Platinum-Based Chemotherapy